Tests GW906 as an added treatment for high blood pressure
Tests GW906 with other drugs in adults whose high blood pressure is not controlled.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
Where in China
- The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Trial code
- NCT07835984
- Record updated
- 23 September 2026
- Original description
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of GW906 Injection (SAL0132) Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.
Inclusion: Age ≥ 18 years, of either sex; Treated hypertension on stable therapy with up to 1 or 2 antihypertensive medications. Stable therapy is defined as having no change in antihypertensive medication or dose within 4 weeks prior to randomization; Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and < 180 mmHg at the randomization visit; Willing to participate in the study and provide written informed consent.
Exclusion: Received an investigational agent within the last 3 months; Secondary hypertension; Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus; History of any cardiovascular event within 12 months; History of intolerance to SC injection(s); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or < 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2; orthostatic hypotension.